An open-label pilot study of Saccharomyces Boulardii for postoperative endoscopic recurrence of Crohn's disease (CD)

Introduction: Endoscopic recurrence of Crohn's disease after curative ileocecal resection (ICR) is reported in up to 70% of patients within 1 year. A significant role of the intestinal flora in the initiation and perpetuation of mucosal inflammation is delineated from therapeutic observations. Probiotics may cause an alteration of intestinal microflora to a less aggressive one. Aims & Methods: This study was performed to assess the efficacy of Saccharomyces boulardii, Yomogi® b.i.d. (Ardeypharm-Berlin, 2.5×109 cells/capsule) for patients with endoscopic recurrence of CD after ICR (i1-i4 according to Rutgeerts et…